LHC Group Inc.

source: coverage-next-full ticker: LHCG step: "01" title: Business Overview — LHC Group Acquisition Case Study created: 2026-05-29

LHCG — Business Overview

Company Summary

LHC Group, Inc. was a Lafayette, Louisiana-based provider of home health, hospice, and community-based post-acute care services. Founded in 1994 by Keith Myers (longtime CEO), the company went public on NASDAQ in 2005 and grew over 18 years through a combination of organic expansion and acquisitions to become the second-largest home health provider in the United States at the time of its acquisition.

On February 22, 2023, LHC Group was acquired by UnitedHealth Group (via its Optum Health subsidiary) for $170.00 per share in cash, representing a total enterprise value of approximately $5.4 billion. The company was delisted from NASDAQ on that date. This research treats LHCG as a completed acquisition case study.

Business Description (as of Acquisition)

LHC Group operated across five service lines:

1. Home Health Services (~71.7% of FY2022 revenue, ~$1.64B)

The core business. Skilled home health includes nursing, physical therapy, occupational therapy, speech therapy, medical social work, and home health aide services. Services are delivered at patients' residences following a hospital discharge, surgery, or onset of a chronic condition. Reimbursement is predominantly Medicare fee-for-service under the Patient Driven Groupings Model (PDGM), with growing managed care exposure.

As of acquisition close, LHC Group operated approximately 230 home health locations across ~35 states.

2. Hospice Services (~11.6% of FY2022 revenue, ~$265M)

Palliative and end-of-life care for patients with a terminal diagnosis and life expectancy of six months or less. Medicare reimbursement is per-diem based. Approximately 100 hospice locations operated.

3. Home and Community-Based Services (HCBS) (~9.7%, ~$221M)

Non-skilled personal care, companionship, and supportive services for elderly and disabled individuals. Funded by Medicaid and state-funded waiver programs. Less capital-intensive than skilled home health.

4. Facility-Based Services (~5.8%, ~$133M)

Includes long-term acute care hospitals (LTACHs) and inpatient rehabilitation services operated as joint ventures or managed services. Smaller segment, being wound down or divested.

5. Health Care Innovations (~1.3%, ~$30M)

Technology-enabled and value-based care services; early-stage; piloting value-based contracts with payers.

Geographic Footprint

• ~35 states at acquisition close
• Concentrated in southeastern and south-central US (Louisiana, Mississippi, Alabama, Texas, Tennessee, Georgia, Florida)
• National expansion via acquisition, particularly following the HCA-Brookdale home health portfolio acquisition in December 2021

Corporate Structure

LHC Group operated primarily through joint ventures with hospital systems. This "joint venture model" was a key differentiator — approximately 50-60% of home health locations were structured as JVs with acute care hospitals (e.g., HCA Healthcare, Ascension, Community Health Systems). The model provided:

• Guaranteed referral flow from hospital system partners
• Lower upfront capital requirements
• Local brand credibility
• Barrier to competitor displacement

History and Growth Strategy

The Almost Family acquisition (2018) was a pivotal strategic move that added significant hospice and home/community-based services capacity and made LHCG a more complete post-acute platform. The HCA-Brookdale acquisition (December 2021, ~$210M) added ~40 locations and deepened the HCA partnership.

Employees

Approximately 30,000 employees at the time of acquisition, the majority clinical (registered nurses, physical therapists, home health aides). Labor represents ~60% of operating costs and was the primary margin pressure in FY2021–FY2022.

Regulatory Environment

LHC Group operated in a heavily regulated industry:

• Medicare PDGM (implemented January 2020): Restructured home health reimbursement from therapy-visit-volume-based to patient-condition-based. Required significant operational adaptation but ultimately preserved unit economics.
• Certificate of Need (CON) laws: ~35 states have CON requirements for home health, creating barriers to new entrant competition (competitive moat).
• PEPPER data: CMS targets high-utilization outlier providers; compliance requires ongoing clinical documentation management.
• State Medicaid regulations: Vary by state for HCBS; waiver program dynamics affect volume.

Why LHC Group Matters as a Case Study

LHC Group's acquisition by UnitedHealth Group at 16x EBITDA illustrates the premium placed on:

1. Scale in home-based care as hospital discharges shift post-acute settings toward home
2. Hospital JV referral networks that are difficult to replicate
3. The payer/provider vertical integration thesis driving UnitedHealth's strategy
4. The ongoing consolidation of a highly fragmented home health industry (~12,000 Medicare-certified home health agencies in the US, with top 10 providers controlling <25% of market)

source: coverage-next-full ticker: LHCG step: "04" title: Financial Snapshot — 5-Year P&L Summary created: 2026-05-29

LHCG — Financial Snapshot

Income Statement Summary (FY2018–FY2022)

All figures in USD millions unless noted. Source: SEC EDGAR XBRL (CIK 0001303313).

EBITDA and Adj. EBITDA estimated from reported figures; Adj. EBITDA adds back stock-based comp, M&A costs, and other non-recurring items.

Revenue Growth Context

• FY2019 +34% growth: Primarily driven by the Almost Family, Inc. acquisition (closed April 2018) — added ~$500M in annualized revenue including hospice and HCBS segments
• FY2020 +13.9% growth: Organic + tuck-in acquisitions; COVID-19 caused Q2 volume dip but Q3/Q4 recovery; COVID MAAP funds inflated cash flow
• FY2021 +7.6% growth: Solid organic growth; HCA-Brookdale acquisition added ~$80M in partial-year contribution
• FY2022 +2.8% growth: Slowest organic growth due to labor shortages constraining admissions capacity; staffing gaps reduced ability to take on new patients

FY2022 Margin Compression — Detailed Analysis

FY2022 was a year of significant earnings pressure from multiple simultaneous headwinds:

Despite the earnings trough, LHCG maintained solid revenue and the underlying business remained cash-generative. Adj. EBITDA of ~$215M vs. $5.4B acquisition price = 25x acquisition EV/Adj. EBITDA on trough earnings — UnitedHealth clearly valued normalized earnings power ($300–325M Adj. EBITDA potential as labor normalized).

Gross Profit Analysis

Gross margin contracted from 41.3% (FY2018) to 38.7% (FY2022):

• Primary driver: Cost of revenue as % of revenue increasing, mainly labor
• Home health gross margin historically ~42–44% (Medicare-heavy mix)
• Hospice gross margin ~48–52% (lower per-visit direct costs, longer patient stays)
• HCBS gross margin ~18–22% (labor-intensive, hourly model)
• Mix shift toward HCBS (lower margin) is a structural headwind

SG&A and Operating Leverage

The SG&A increase in FY2022 reflects:

• ~$20M in merger/acquisition-related transaction costs (UHG deal)
• Administrative salary inflation
• Technology and compliance investments

Adjusted EPS Context

Reported FY2022 EPS of $1.30 was heavily distorted by:

• Merger-related costs (~$20M pre-tax = ~$0.50/share)
• Elevated SBC ($20M = ~$0.50/share non-cash)
• Labor cost peaks that were already normalizing in late 2022

Adjusted EPS for FY2022 was estimated at ~$4.50–$5.00 — more representative of normalized earnings power, and closer to the prior year $3.69 GAAP EPS.

Key Observations

1. Steady compounder pre-FY2022: LHCG grew revenue ~69% from FY2018 to FY2022 (CAGR ~14%, acquisition-assisted); EBITDA roughly doubled
2. FY2022 was a temporary trough: Labor normalization, deal cost removal, and census rebuild would have materially improved FY2023 earnings had LHCG remained public
3. Acquisition premium justified on normalized earnings: At $5.4B EV vs. ~$300M normalized EBITDA = ~18x normalized — premium to peers but not outrageous for a high-quality JV-model platform
4. Gross margin durability: Despite labor pressure, gross margin never fell below 38%; demonstrates pricing power and mix resiliency

source: coverage-next-full ticker: LHCG step: "12" title: Catalysts — Near-Term Events and Bull/Bear Case created: 2026-05-29

LHCG — Catalysts

Context: Pre-Acquisition Catalyst Analysis (as of Q1 2022)

This section analyzes the catalysts that existed for LHCG as a standalone public company immediately before and around the time of the March 2022 UnitedHealth acquisition announcement. The relevant question for investors: what would have driven the stock re-rating had no deal materialized?

Catalysts That Were Pending (Pre-Deal, Q1 2022)

1. Labor Cost Normalization (12–18 Month Catalyst)

The travel nurse/contract labor premium was expected to normalize through 2022–2023 as hospital staffing crises eased. Management guided for improvement; the stock was pricing in continued pressure. Evidence of sequential improvement in cost per episode would have been a re-rating trigger.

2. CMS FY2022 Rate Resolution

The final FY2022 home health payment rule and the ongoing fight against CMS's behavioral offset assumption were pivotal. A more favorable-than-feared rate outcome was a potential positive catalyst for the sector.

3. HCA-Brookdale Integration Completion

The HCA-Brookdale acquisition (December 2021) was still in early integration. Full revenue and EBITDA contribution in FY2022–FY2023 would have added ~$80–100M incremental revenue and improved blended margins once integration costs abated.

4. Almost Family Synergy Realization

Years 4–5 post-Almost Family acquisition were expected to deliver mature synergies. Cost optimizations in the combined administrative infrastructure were still in progress.

5. Value-Based Care Contract Wins

LHCG's Health Care Innovations segment and MA value-based contracts had the potential to expand into a higher-margin revenue stream. A meaningful contract announcement with a large MA plan would have signaled the long-term margin recovery path.

6. M&A Announcement (Deal Itself — The Realized Catalyst)

On March 29, 2022, UnitedHealth Group announced the $170/share acquisition — the most powerful catalyst of all. The stock immediately gapped from ~$130 to ~$168–170 (a ~30% single-day move), validating that the market had been significantly undervaluing LHCG on near-term earnings power rather than strategic/intrinsic value.

Industry Catalysts (Post-Acquisition Context)

For the broader home health sector following LHCG's exit from the public market:

Strategic Bidding War Scenarios

• The LHCG deal triggered immediate speculation about Amedisys (AMED) as the next target
• Amedisys did receive UnitedHealth and Optum bids; the subsequent deal demonstrated continued appetite for large-scale home health assets
• Addus HomeCare (ADUS) and Enhabit (EHAB) traded at M&A speculation premiums post-LHCG deal

CMS Value-Based Purchasing Expansion

HHVBP program expansion nationwide in FY2023 favored high-quality large operators; a positive structural catalyst for the remaining publicly traded peers.

Bull Case

• LHCG stock was a buy before the deal announcement because the market was anchoring to trough FY2022 GAAP EPS ($1.30) rather than normalized earnings power (~$5.00 adjusted); a patient investor who recognized the labor cost cycle peak and strategic M&A optionality in the JV network earned a ~35–40% return in under 12 months
• The hospital JV model created a structural referral advantage that no competitor could replicate without years of hospital system partnership development — making LHCG the most defensible platform in home health and the most rational acquisition target for a payer seeking vertical integration
• Home health sector demographic tailwinds (baby boomer aging wave through 2030+), CMS policy preference for home-based over institutional care, and a long acquisition pipeline of small agencies trading at 4–8x EBITDA meant LHCG had multiple avenues to compound capital at above-average returns even without an M&A exit

Bear Case

• CMS's aggressive behavioral adjustment to PDGM rates risked a permanent step-down in home health reimbursement that would have structurally compressed the industry's earning power — particularly dangerous for an operator with $733M in net debt that needed EBITDA to recover
• Medicare Advantage's continued growth toward a 60%+ share of Medicare enrollments would have created a multi-year reimbursement headwind as MA plan negotiating leverage increased and per-episode rates drifted further below traditional Medicare FFS — LHCG's JV referral advantages would not have protected it from payer-side margin compression
• The labor market normalization thesis could have extended far longer than expected, given structural nursing shortages (BLS projected ~$195K annual new RN demand through 2031 vs. constrained supply) and persistent wage inflation — a FY2023 without margin recovery would have triggered leverage concerns and potentially forced dilutive equity issuance at depressed prices